Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed against Keryx Biopharmaceuticals, Inc. (KERX...
August 10 2016 - 3:57PM
Business Wire
Bragar Eagel & Squire, P.C. announces that a class action
lawsuit has been filed in the United States District Court for the
Southern District of New York on behalf of all persons or entities
who acquired Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
securities between February 25, 2016 and August 1, 2016 (the “Class
Period”).
The complaint filed in this lawsuit alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts
about the Company’s business, operations, and prospects.
Specifically, Defendants made false and/or misleading statements
and/or failed to disclose: (1) that the Company was experiencing
production-related difficulties in converting API to finished drug
product; (2) that the issue was resulting in decreased production
yields of finished drug product; (3) that, as a result, the Company
would, and did exhaust its reserve of finished drug product; and
(4) that, as a result of the foregoing, Defendants’ statements
about Keryx’s business, operations, and prospects, were false and
misleading and/or lacked a reasonable basis.
If you acquired Keryx securities during the Class Period or
continue to hold shares purchased prior to the Class Period, have
information or would like to learn more about these claims, or have
any questions concerning this announcement or your rights or
interests with respect to these matters please contact J. Brandon
Walker, Esq. by email at investigations@bespc.com, or telephone at
(212) 355-4648, or by filling out this contact form. There is no
cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm
concentrating in commercial and securities litigation. For
additional information, please go to www.bespc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160810006099/en/
Bragar Eagel & Squire, P.C.J. Brandon Walker,
Esq.212-355-4648investigations@bespc.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024